利格列汀对血管功能的影响:一项随机安慰剂对照研究
这项随机双盲安慰剂对照试验在40例2型糖尿病患者中比较利格列汀5mg/d与安慰剂治疗12周的效果。利格列汀与轴突反射依赖性血管舒张增加相关(P=.05),内皮依赖性微血管反应性呈增加趋势(P=.07),并伴随干扰素γ、白细胞介素-6、白细胞介素-12和巨噬细胞炎症蛋白-1浓度较安慰剂降低。利格列汀对线粒体功能、大血管功能或内皮祖细胞无显著影响。
要点
- 利格列汀5mg/d治疗12周与轴突反射依赖性血管舒张增加相关(P=.05)。
- 内皮依赖性微血管反应性呈增加趋势(P=.07),未达统计学显著。
- 利格列汀组干扰素γ(P<.05)、白细胞介素-6(P=.03)、白细胞介素-12(P<.03)和巨噬细胞炎症蛋白-1(P<.04)浓度较安慰剂降低。
核心结论
- 利格列汀倾向于改善2型糖尿病患者的内皮和神经血管微血管功能,并与炎症标志物降低相关。
- 利格列汀对线粒体功能、大血管功能或内皮祖细胞无显著影响。
研究设计与样本
- 随机、双盲、安慰剂对照试验,在一家拥有大量2型糖尿病转诊来源的三级医疗中心进行。
- 40例2型糖尿病患者接受利格列汀5mg/d或安慰剂治疗12周。
主要发现
- 利格列汀与轴突反射依赖性血管舒张增加相关(P=.05)。
- 观察到内皮依赖性微血管反应性增加的趋势(P=.07)。
- 与安慰剂相比,利格列汀治疗后干扰素γ浓度降低(P<.05)。
- 与安慰剂相比,利格列汀治疗后白细胞介素-6浓度降低(P=.03)。
- 与安慰剂相比,利格列汀治疗后白细胞介素-12浓度降低(P<.03)。
关键数值与推荐
- 微血管功能采用激光多普勒联合离子导入评估。
- 大血管功能采用肱动脉血流介导的舒张评估。
- 线粒体功能通过磁共振波谱测量小腿肌肉磷-31代谢物变化评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The dipeptidyl peptidase-4 inhibitor, linagliptin, possesses pleiotropic vasodilatory, antioxidant, and anti-inflammatory properties in animals, independent of its glucose-lowering properties. Although large, randomized clinical trials are being conducted to better evaluate the efficacy and safety of linagliptin on cardiovascular outcomes, little is known about its effects on vascular function in humans. OBJECTIVE: This study sought to evaluate the effect of linagliptin on surrogates of vascular and mitochondrial function. DESIGN AND SETTING: This was a randomized, double-blind, placebo-controlled trial at a tertiary care center with a large type 2 diabetes referral base. PATIENTS AND INTERVENTION: Forty participants with type 2 diabetes were included in a 12-wk treatment of either linagliptin 5mg/d or placebo. MAIN OUTCOME MEASURES: Micro- and macrovascular functions were assessed using laser Doppler coupled with iontophoresis and with brachial flow-mediated dilation, respectively. Mitochondrial function was assessed by phosphorus-31 metabolites changes in the calf muscle measured by magnetic resonance spectroscopy. Circulating endothelial progenitor cells, as well as inflammatory cytokines, growth factors, and biomarkers of endothelial function were also quantified. RESULTS: Linagliptin was associated with an increase in axon reflex-dependent vasodilation, a marker of neurovascular function (P = .05). A trend indicating increased endothelium-dependent microvascular reactivity was observed (P = .07). These were associated with decreases in concentrations of IFNγ (P < .05), IL-6 (P = .03), IL-12 (P < .03), and MIP-1 (P < .04) following linagliptin treatment when compared with placebo. CONCLUSIONS: This study demonstrates that linagliptin tends to improve endothelial and neurovascular microvascular function and is associated with decreased markers of inflammation in patients with type 2 diabetes. There was no significant effect of linagliptin on mitochondrial function, macrovascular function, or endothelial progenitor cells.
引用
- Baltzis D, Dushay JR, Loader J, et al. Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study. J Clin Endocrinol Metab. 2016. PMID: 27583476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。